Following Positive End of Phase 2 Meeting with FDA.
Lyon, France, and Cambridge, MA, May 2, 2023 — Amolyt Pharma, a global company
specialized in developing therapeutic peptides for rare endocrine and related diseases, today
announced that it will initiate its Phase 3 clinical trial of eneboparatide, a long-acting
parathyroid hormone 1 (PTH1) receptor agonist, in patients with hypoparathyroidism following
the receipt of End-of-Phase 2 guidance from the U.S. Food and Drug Administration (FDA).